FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213565503> ?p ?o ?g. }

• W3213565503 endingPage "207" @default.
• W3213565503 startingPage "198" @default.
• W3213565503 abstract "Rationale: The INCREASE study of inhaled treprostinil met its primary endpoint of change in 6-minute-walk distance at Week 16. In addition, there were significantly fewer clinical worsening events in patients receiving inhaled treprostinil. However, the incidence of multiple events in the same patient is unknown. Objectives: This post hoc analysis evaluated the effect of continued treatment with inhaled treprostinil on the frequency and impact of multiple disease progression events. Methods: Patients enrolled in INCREASE were analyzed for disease progression events, defined as at least 15% decline in 6-minute-walk distance, exacerbation of underlying lung disease, cardiopulmonary hospitalization, lung transplantation, at least 10% decline in forced vital capacity, or death during the duration of the 16-week study. Measurements and Main Results: In total, 147 disease progression events occurred in the inhaled treprostinil group (89/163 patients, 55%) compared with 215 events (109/163 patients, 67%) in the placebo group (P = 0.018). There was a lower incidence of each disease progression component in the inhaled treprostinil group: 6-minute-walk distance decline (45 vs. 64 events), lung disease exacerbation (48 vs. 72 events), FVC decline (19 vs. 33), cardiopulmonary hospitalization (23 vs. 33 events), and death (10 vs. 12). Fewer patients receiving inhaled treprostinil had multiple progression events compared with those receiving the placebo (35 vs. 58, 22% vs. 36%; P = 0.005). Conclusions: Patients who received inhaled treprostinil were significantly less likely to experience further disease progression events after an initial event compared with patients receiving placebo. These results support the continuation of inhaled treprostinil despite the occurrence of disease progression in clinical practice." @default.
• W3213565503 created "2021-11-22" @default.
• W3213565503 creator A5002591463 @default.
• W3213565503 creator A5021150751 @default.
• W3213565503 creator A5024018507 @default.
• W3213565503 creator A5025457428 @default.
• W3213565503 creator A5029042843 @default.
• W3213565503 creator A5031652756 @default.
• W3213565503 creator A5052485494 @default.
• W3213565503 creator A5060885607 @default.
• W3213565503 creator A5067760662 @default.
• W3213565503 creator A5087280138 @default.
• W3213565503 date "2022-01-15" @default.
• W3213565503 modified "2023-10-14" @default.
• W3213565503 title "Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial" @default.
• W3213565503 cites W13250750 @default.
• W3213565503 cites W2058041469 @default.
• W3213565503 cites W2083977896 @default.
• W3213565503 cites W2123137799 @default.
• W3213565503 cites W2171738220 @default.
• W3213565503 cites W2440054067 @default.
• W3213565503 cites W2485988367 @default.
• W3213565503 cites W2604367936 @default.
• W3213565503 cites W2607149709 @default.
• W3213565503 cites W2770589251 @default.
• W3213565503 cites W2883908584 @default.
• W3213565503 cites W2888503862 @default.
• W3213565503 cites W2901934212 @default.
• W3213565503 cites W2904463477 @default.
• W3213565503 cites W3108021021 @default.
• W3213565503 cites W3119793303 @default.
• W3213565503 cites W3137016834 @default.
• W3213565503 cites W3213565503 @default.
• W3213565503 doi "https://doi.org/10.1164/rccm.202107-1766oc" @default.
• W3213565503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34767495" @default.
• W3213565503 hasPublicationYear "2022" @default.
• W3213565503 type Work @default.
• W3213565503 sameAs 3213565503 @default.
• W3213565503 citedByCount "25" @default.
• W3213565503 countsByYear W32135655032022 @default.
• W3213565503 countsByYear W32135655032023 @default.
• W3213565503 crossrefType "journal-article" @default.
• W3213565503 hasAuthorship W3213565503A5002591463 @default.
• W3213565503 hasAuthorship W3213565503A5021150751 @default.
• W3213565503 hasAuthorship W3213565503A5024018507 @default.
• W3213565503 hasAuthorship W3213565503A5025457428 @default.
• W3213565503 hasAuthorship W3213565503A5029042843 @default.
• W3213565503 hasAuthorship W3213565503A5031652756 @default.
• W3213565503 hasAuthorship W3213565503A5052485494 @default.
• W3213565503 hasAuthorship W3213565503A5060885607 @default.
• W3213565503 hasAuthorship W3213565503A5067760662 @default.
• W3213565503 hasAuthorship W3213565503A5087280138 @default.
• W3213565503 hasBestOaLocation W32135655031 @default.
• W3213565503 hasConcept C120665830 @default.
• W3213565503 hasConcept C121332964 @default.
• W3213565503 hasConcept C126322002 @default.
• W3213565503 hasConcept C142724271 @default.
• W3213565503 hasConcept C203092338 @default.
• W3213565503 hasConcept C204787440 @default.
• W3213565503 hasConcept C27081682 @default.
• W3213565503 hasConcept C2776432619 @default.
• W3213565503 hasConcept C2777014857 @default.
• W3213565503 hasConcept C2780930700 @default.
• W3213565503 hasConcept C535046627 @default.
• W3213565503 hasConcept C61511704 @default.
• W3213565503 hasConcept C71924100 @default.
• W3213565503 hasConceptScore W3213565503C120665830 @default.
• W3213565503 hasConceptScore W3213565503C121332964 @default.
• W3213565503 hasConceptScore W3213565503C126322002 @default.
• W3213565503 hasConceptScore W3213565503C142724271 @default.
• W3213565503 hasConceptScore W3213565503C203092338 @default.
• W3213565503 hasConceptScore W3213565503C204787440 @default.
• W3213565503 hasConceptScore W3213565503C27081682 @default.
• W3213565503 hasConceptScore W3213565503C2776432619 @default.
• W3213565503 hasConceptScore W3213565503C2777014857 @default.
• W3213565503 hasConceptScore W3213565503C2780930700 @default.
• W3213565503 hasConceptScore W3213565503C535046627 @default.
• W3213565503 hasConceptScore W3213565503C61511704 @default.
• W3213565503 hasConceptScore W3213565503C71924100 @default.
• W3213565503 hasFunder F4320309555 @default.
• W3213565503 hasIssue "2" @default.
• W3213565503 hasLocation W32135655031 @default.
• W3213565503 hasLocation W32135655032 @default.
• W3213565503 hasLocation W32135655033 @default.
• W3213565503 hasOpenAccess W3213565503 @default.
• W3213565503 hasPrimaryLocation W32135655031 @default.
• W3213565503 hasRelatedWork W2028737167 @default.
• W3213565503 hasRelatedWork W2112264559 @default.
• W3213565503 hasRelatedWork W2275480158 @default.
• W3213565503 hasRelatedWork W2557131790 @default.
• W3213565503 hasRelatedWork W2904517516 @default.
• W3213565503 hasRelatedWork W2981515574 @default.
• W3213565503 hasRelatedWork W3200621203 @default.
• W3213565503 hasRelatedWork W3205260038 @default.
• W3213565503 hasRelatedWork W4309918096 @default.
• W3213565503 hasRelatedWork W4384664590 @default.
• W3213565503 hasVolume "205" @default.
• W3213565503 isParatext "false" @default.

• next